Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Brief international cognitive assessment for multiple sclerosis (BICAMS): A danish validation study of sensitivity in early stages of MS

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Biomarkers of inflammation and epithelial barrier function in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Fibrinogen: A potential biomarker for predicting disease severity in multiple sclerosis

    Research output: Contribution to journalReviewpeer-review

  3. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Magnetic resonance imaging at baseline and follow-up to differentiate between pediatric monophasic acquired CNS demyelination and MS

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Biomarkers of inflammation and epithelial barrier function in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Cognitive impairment is highly prevalent in multiple sclerosis (MS). Due to the lack of specialized neuropsychological resources in many MS clinics, a brief cognitive monitoring tool that can be administered by other MS clinic staff is needed. BICAMS (Brief International Cognitive As-sessment for Multiple Sclerosis) has been developed and recommended by MS experts to monitor MS-related cognitive impairment. International validations of the tool are warranted.

OBJECTIVE: The primary aim of the study was to establish a Danish translation of BICAMS as a feasible cognitive monitoring tool and to provide a Danish contribution to the international validation of BI-CAMS. A secondary aim was to determine if BICAMS correlated with self-reported cognition. The study population comprised people with MS (pwMS) with relatively early MS and newly diagnosed.

METHODS: 65 pwMS were compared to healthy controls (HCs) matched on age, sex and education. PwMS and controls completed the BICAMS test battery which includes the Symbol Digit Modalities Test (SDMT, oral version), California Verbal Learning Test-II (CVLT-II) and the Brief Visuospatial Memory Test-Revised (BVMT-R). In addition, self-reported cognition, fatigue, depression and quality of life were assessed. To evaluate the reliability of the BICAMS test, all participants were retested 2-3 weeks later with alternate versions of the tests.

RESULTS: Mean age of the MS group was 37.2 years; 63% were female and all pwMS had a relapsing-remitting disease course. MS disease duration was relatively short; mean disease duration was 3.9 years and 32 of 65 pwMS (49%) were newly diagnosed with MS, i.e. diagnosed within the last 2 years. Mean EDSS was 1.8 with a span from 0-4. Comparison of the groups showed that the MS group performed significantly below the control group on the 3 BICAMS measures: SDMT (p<0.005), CVLT-II (p<0.05) and BVMT-R (p<0.05). When the results were controlled for influence from depression and fatigue by regression analysis, group differences were limited to the SDMT (p<0.05) and the BVMT-R (p<0.05) and these group differences were only found at the retest session. The BICAMS measures were reliable over time (r = 0.90 for SDMT, r = 0.82 for CVLT-II and r = 0.68 for BVMT-R). 32.3% of the MS population was cognitively impaired on at least one of the 3 BICAMS tests (defined as -1.5 SD compared to HCs). In the MS group 20% were impaired on the SDMT; 16.9% were impaired on the BVMT-R and 10.7% were impaired on the CVLT-II. There was no relationship between BICAMS test-scores and subjectively reported cognition, fatigue or depression.

CONCLUSION: The Danish translation of BICAMS was a reliable and feasible cognitive assessment tool. This finding was confirmed even in an MS population characterized by relatively early MS and high cognitive reserve. Frequency of cognitive dysfunction detected by BICAMS in this study was relatively low due to population characteristics.

Original languageEnglish
JournalMultiple Sclerosis and Related Disorders
Volume37
Pages (from-to)101458
ISSN2211-0348
DOIs
Publication statusPublished - Jan 2020

    Research areas

  • Adolescent, Adult, Cognitive Dysfunction/diagnosis, Denmark, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting/complications, Neuropsychological Tests/standards, Reproducibility of Results, Sensitivity and Specificity, Young Adult

ID: 61517627